What's Happening?
The START Center for Cancer Research has appointed Dr. Navid Hafez as the Director of Clinical Research at its new Los Angeles site. This site is part of the START Network, which is the largest community-based network specializing in early-phase oncology
trials. Dr. Hafez brings over a decade of experience in academic and clinical research, having previously served as an attending physician at The Angeles Clinic and Research Institute and as an Assistant Professor of Medical Oncology at Yale School of Medicine. His expertise includes targeted therapies, immuno-oncology, and translational research. The Los Angeles site, in partnership with the Los Angeles Cancer Network (soon to be Oncura Health), aims to serve a diverse population of over 14 million people, providing access to early-phase trials for various cancer types.
Why It's Important?
The appointment of Dr. Hafez and the establishment of the START Los Angeles site are significant for the advancement of cancer research and treatment. By expanding access to early-phase oncology trials, the site offers new therapeutic options to a large and diverse patient population. This initiative is crucial in addressing the need for more inclusive and accessible cancer care, particularly in community-based settings. The integration of clinical research into patient care pathways can lead to more personalized and effective treatment strategies, potentially improving outcomes for cancer patients. Additionally, the collaboration with Oncura Health highlights a commitment to comprehensive, whole-person care, which is essential in managing the complex needs of cancer patients.
What's Next?
With the launch of the Los Angeles site, START aims to enhance its research capabilities and expand its network of early-phase clinical trials. Dr. Hafez's leadership is expected to drive the development of innovative cancer therapies and increase trial participation among diverse populations. The partnership with Oncura Health will likely focus on integrating advanced medical oncology with coordinated care, ensuring that patients receive comprehensive support throughout their treatment journey. As the site becomes operational, it will be important to monitor its impact on trial enrollment and patient outcomes, as well as its contributions to the broader field of oncology research.
